Literature DB >> 2233276

Altered ketone body metabolism during gram-negative sepsis in the rat.

S Lanza-Jacoby1, E Rosato, G Braccia, A Tabares.   

Abstract

To investigate why blood ketone bodies are depressed during sepsis, the production and utilization of ketone bodies was studied in fasted control, fasted, Escherichia coli-treated, fed control, and fed E coli-treated rats. Gram-negative sepsis was induced by intravenous (IV) injection of 8 x 10(7) live colonies of E coli per 100 g body weight. Food was removed from the fasted rats after E coli injection. Fed rats were infused intragastrically with a nutritionally adequate diet for 5 days before inducing sepsis. Twenty-four hours after E coli injection, blood ketone bodies were reduced in fasted septic rats and fed septic rats compared with their respective control rats. Ketogenesis and oxidation of labeled palmitate was not altered in hepatocytes from fasted E coli-treated rats. Yet, ketogenesis declined significantly in hepatocytes from fed E coli-treated rats. Oxidation of labeled palmitate was also significantly reduced in hepatocytes from fed E coli-treated rats. Utilization of ketone bodies as measured by the incorporation of [3-14C]beta-hydroxybutyrate into CO2, increased over threefold in the diaphragm, 12% in the heart, and 19% in the kidneys from the fasted E coli-treated rats. In the fed state, incorporation of [3-14C]beta-hydroxybutyrate into CO2 was elevated fivefold in the heart, fourfold in the diaphragm, and over threefold in the kidneys from the septic rats. These results suggest that in the fasted state, plasma ketone bodies remain low during gram-negative sepsis because peripheral tissues use more ketone bodies and because liver ketogenesis is not increased to compensate for the increased utilization. In the fed state, the reduction in blood ketone bodies appears to be attributed to both impaired ketogenic capacity and increased peripheral utilization.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2233276     DOI: 10.1016/0026-0495(90)90087-s

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis.

Authors:  Kenneth R Feingold; Carl Grunfeld; Josef G Heuer; Akanksha Gupta; Martin Cramer; Tonghai Zhang; Judy K Shigenaga; Sophie M Patzek; Zoe W Chan; Arthur Moser; Holly Bina; Alexei Kharitonenkov
Journal:  Endocrinology       Date:  2012-04-02       Impact factor: 4.736

2.  PPARα augments heart function and cardiac fatty acid oxidation in early experimental polymicrobial sepsis.

Authors:  Stephen W Standage; Brock G Bennion; Taft O Knowles; Dolena R Ledee; Michael A Portman; John K McGuire; W Conrad Liles; Aaron K Olson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-11-23       Impact factor: 4.733

3.  A proteomic analysis of liver mitochondria during acute endotoxemia.

Authors:  Elliott D Crouser; Mark W Julian; Jennifer E Huff; David V Mandich; Kari B Green-Church
Journal:  Intensive Care Med       Date:  2006-06-02       Impact factor: 17.440

Review 4.  When a calorie isn't just a calorie: a revised look at nutrition in critically ill patients with sepsis and acute kidney injury.

Authors:  Mridula Nadamuni; Andrea H Venable; Sarah C Huen
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-06-10       Impact factor: 3.416

5.  Infection decreases fatty acid oxidation and nuclear hormone receptors in the diaphragm.

Authors:  Kenneth R Feingold; Arthur Moser; Sophie M Patzek; Judy K Shigenaga; Carl Grunfeld
Journal:  J Lipid Res       Date:  2009-05-14       Impact factor: 5.922

6.  PPARα contributes to protection against metabolic and inflammatory derangements associated with acute kidney injury in experimental sepsis.

Authors:  Takuma Iwaki; Brock G Bennion; Erin K Stenson; Jared C Lynn; Cynthia Otinga; Danijel Djukovic; Daniel Raftery; Lin Fei; Hector R Wong; W Conrad Liles; Stephen W Standage
Journal:  Physiol Rep       Date:  2019-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.